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Abstract 
 
Background: Host genetic factors may significantly influence the ability to clear 
hepatitis C virus (HCV) following infection. HCV are associated with very-low-
density lipoproteins (VLDL) and low-density-lipoproteins (LDL) in the host’s 
circulation. Apolipoprotein E (APO-E) is found in VLDL and binds to potential 
receptors involved in HCV entry into cells, the LDL receptor and the scavenger 
receptor protein, SR-B1. The APO-E gene is polymorphic with three alleles coding 
for 3 isoforms:  Apo-ε2, Apo-ε3 and Apo-ε4. The aim of this study was to assess if 
these functional polymorphisms determine disease outcome in HCV infected 
individuals. 
Methods: The APOE genotype was determined in 420 Northern European patients 
with evidence of exposure to HCV. Genotype and allele distribution were compared 
with those of 288 healthy controls and progression of liver disease and viral clearance 
were analysed according to APOE allele status.  
Results: The APOE*E2 and APOE*E4 alleles were both associated with a reduced 
likelihood of chronic infection (OR = 0.39, CI 0.211 – 0.728, p = 0.003 and OR = 0.6, 
CI 0.38 – 0.96, p = 0.032) and there was a notable absence of the E2E2 genotype in 
the HCV antibody positive group compared with the control population (p = 0.0067). 
Overall the genotypes carrying the E2 allele (E2,E3 and E2,E4) were associated with 
the equivalent of a 3 – 5 fold reduction in risk of chronic HCV infection (GRR = 0.36 
and 0.20; respectively).  
Conclusion: This study indicates that functional APOE gene polymorphisms may be a 
determinant of outcome in HCV infection. We hypothesise that the E2 allele may 
protect against viral persistence via defective binding of HCV lipo-viral particles to 
the cellular receptors involved in entry of these infectious particles. 
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Introduction  
Hepatitis C virus (HCV) infection is a major global health problem, infecting more 
than 170 million people worldwide 1. Some newly infected patients recover 
spontaneously but the majority progress to chronic infection, so that HCV infection is 
now the leading cause of cirrhosis, hepatocellular cancer and liver transplantation in 
the Western world 2.  
Persisting strong CD8+ T-cell responses are observed in the majority with resolved 
HCV infection 3 but the role of host factors in viral clearance and disease progression 
remains unclear. There is some evidence that host genetic factors are implicated in the 
outcome following HCV infection 4. Specific HLA haplotypes have been associated 
with a significantly increased likelihood of  viral clearance, including the HLA-
DRB1*1101-DQB1*0301, DRB1*1104-DQB1*0301 and  DRB1*0401-DQB1*0301 
haplotypes 4-7. In addition recent data suggests that inherited variation in the killer 
inhibitory receptor genes may play a significant role in determining the host response 
to HCV infection 8. 
Other host factors associated with disease progression in chronic HCV include male 
sex, age at infection, excessive alcohol use, total cholesterol level and insulin 
resistance 9. In addition there is now considerable accumulating evidence to suggest a 
relationship between hepatitis C virus and lipid metabolism 10. During the early stages 
of acute HCV infection in chimpanzees host genes involved in lipid metabolism are 
differentially regulated 11. In patients with chronic HCV serum cholesterol is 
significantly lower than in appropriately matched controls 12, particularly in HCV 
genotype 3 infection 13 14 and this metabolic effect is fully reversible after successful 
HCV eradication 15 The association of HCV infection with hypocholesterolaemia has 
been confirmed in HIV- infected patients 16 and in patients with porphyria cutanea 
tarda 17. In many studies the hypocholesterolaemia has been associated with a 
decrease in apolipoprotein B (ApoB) in comparison with healthy controls 12 17 18 and 
ApoB levels negatively correlate with hepatic steatosis and viral load 18. Furthermore, 
HCV viral load can be reduced by H.E.L.P. apheresis, which is an established and 
approved therapy for hypercholesterolaemia 19. 
HCV RNA containing particles are consistently found in the low-density fractions of 
serum and this fraction has been shown to be highly infectious 20. Further 
characterisation of these low density HCV RNA containing particles (lipo-viral 
particles (LVP)) has shown they efficiently bind and enter hepatocyte cell-lines, up-
regulation of the low density lipoprotein receptor (LDLr) increases their 
internalisation and binding of HCV-LVP can be blocked by anti-ApoB and anti-
apolipoprotein E (ApoE) 21 22. This is consistent with other studies showing that 
endocytosis of HCV can be mediated by LDLr 23 24. LDLr, a candidate receptor for 
HCV, normally transports 2 different classes of cholesterol containing lipoprotein 
particles into cells: LDL, which contains a single copy of ApoB-100 and VLDL, 
which contains multiple copies of ApoE.  
Recent studies with retrovirus/HCV pseudovirus particles 25 suggest that attachment 
to hepatocytes is via the scavenger receptor protein, SR-B1, with entry into the cell 
via a co-receptor CD-81 dependent pathway 26 27. SR-B1, which is expressed 
primarily in the liver, is a key component in the reverse cholesterol transport pathway, 
and recognizes a broad variety of lipoprotein ligands, including HDL, LDL, VLDL 
and oxidised LDL 28-30. 
 Apolipoprotein E, a ligand for both LDLr and SR-B1, is a polymorphic protein 
arising from 3 alleles at a single gene locus. The three major isoforms, Apo-ε2, Apo-
ε3, and Apo-ε4, differ from one another by single amino acid substitutions, a change 
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which has profound functional consequences at both cellular and molecular levels. 
Apo-ε3 seems to be the wild type isoform with normal function, while Apo-ε2 binds 
poorly to LDLr and Apo-ε4 induces a down-regulation of  LDLr 31.  
A previous study of APOE gene polymorphisms in HCV infection suggested 
decreased severity of liver disease in patients with the E4 allele 32. As apolipoprotein 
E is a ligand for the HCV receptor candidates LDLr and SR-B1 and in view of the 
considerable evidence suggesting that cholesterol and fatty acid pathways may play a 
role in HCV replication and infection, the aim of this study was to determine whether 
the common functional polymorphisms of the APOE gene can influence the clinical 
outcome of HCV infection.   
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Patients and Methods 
Patients 
5 mls of whole blood was obtained from 420 Caucasian HCV antibody positive 
patients recruited from two centres, the joint hepatitis clinic of the Freeman Hospital, 
Newcastle-upon-Tyne, England (n=241) and St. James’s Hospital, Dublin, Ireland 
(n=179) 33. 5 mls of whole blood was also collected from 288 healthy adult volunteers 
(controls) to assess the apolipoprotein E genotype distribution in the healthy 
population 34. 
 HCV viral RNA was tested in all HCV antibody positive patients using the Amplicor 
reverse transcriptase polymerase chain reaction (PCR) assay (Roche). 312 patients 
were HCV RNA positive on at least two occasions indicating a persistent or chronic 
infection, whereas 108 patients were HCV RNA negative on at least two occasions, 
indicating spontaneously resolved infection. 
Liver biopsies were available on 209 patients with evidence of chronic infection. Each 
biopsy was scored by a single observer, Prof A.D. Burt, using the Ishak scoring 
system 35. Biopsies were graded for necroinflammation on a scale of 0-16 and fibrosis 
on a scale of 0-6 [fibrosis stage of 5 or 6 indicated severe disease, 2-4 moderate 
disease and 0 or 1 mild disease]. An estimate of the rate of fibrosis was made on 178 
of these patients. A date of infection was either estimated in intravenous drug users 
(IVDU) as the date when IVDU started, or was calculated as the date of exposure to 
infected blood or the date of a one off/short period of IVDU. The Ishak stage of 
fibrosis was divided by the time in years from date of infection to first biopsy to give 
a calculation of the rate of fibrosis. Rapid progression was identified as patients 
progressing to cirrhosis within 20yrs (a rate of fibrosis >0.25/yr). In this subgroup of 
patients, data on alcohol use, age at biopsy, sex and mode of infection were also 
collected; all data and results were entered into a Microsoft® AccessTM database.  
Apolipoprotein E genotyping 
Genomic DNA was isolated from 2mls of whole blood using QIAamp® midi kitsTM 
(Quiagen® Ltd, Crawley, UK). A 227bp product of the APOE gene was amplified 
using a pair of sequence specific primers in a standard PCR reaction 36. Briefly; 
approximately 100ng of DNA was amplified in a 50µl reaction mix containing 2.5µl 
of 100% DMSO, 1.5mM MgCl2, 10mM tris-HCl, 50mM KCL, 0.5µM of each primer, 
200µM of each nucleotide and 2.5U of Taq polymerase (ABGENE®, Epsom, Surrey, 
UK). Amplification conditions were as follows: 2 minutes at 950C and then 40 cycles 
of 2 minutes at 950C, 2 minutes at 650C and 2 minutes at 720C, and a final extension 
for 5 minutes at 720C. All PCR batches included a water (DNA free) negative control 
and samples of known genotype. All genotypes were assigned by two independent 
investigators and any ambiguous genotypes were repeated. The 227-bp product was 
sub-aliquoted into duplicate reaction tubes and subject to digestion with two different 
restriction endonucleases AflIII and HaeI1; digestions were performed with 25U of 
each enzyme at room temperature for a minimum of 3 hours. The resulting restriction 
fragments were separated on 3% agarose gels and the bands were visualised using 
ethidium bromide staining on a UV trans-illuminator and documented on an 
AlphaImager TM 2200 Documentation and Analysis System (AlphaInnotech Corp., 
USA). AflIII digests the PCR amplicons of the APOE*2 and E3 alleles only creating 
bands of 117bp and 50bp (amplicons of E4 do not digest leaving the 227 bp amplicon 
intact). HaeII digests the E3 and E4 amplicons only resulting in bands of 195bp and 
32bp (amplicons of the E2 allele are not digested leaving an intact 227bp amplicon). 
Thus, by comparing the restriction patterns for the two digests on every sample we 
can assign composite genotypes for E2,E2: E2,E3: E3,E3: E2,E4; E3,E4 and E4,E4  
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Statistical Analysis 
Genotype and allele distribution were compared using Stata. As the E3 allele is 
associated with normal APOE activity the risk for the common (wild type) genotype 
E3,E3 was fixed (at 1) and risk for all other genotypes are reported relative to this. In 
the whole HCV antibody positive cohort (n=420) the following comparisons of allele 
and genotype distribution were made: 
• Control group (n = 288) versus HCV exposed (HCV antibody positive) 
population.  
• Chronic HCV infection (n = 312) versus spontaneously resolved (cleared) 
infection (n = 108). 
In the subgroup with chronic HCV infection whose liver biopsies were scored by a 
single observer the following comparisons of allele and genotype distribution were 
made: 
• Severe liver disease versus mild/moderate chronic hepatitis (n=209) 
• Slow fibrosis progression versus rapid fibrosis progression (n=178) 
 
Risk is reported as Genotype Relative Risk (GRR) for comparison of genotype 
distribution and Odds Ratio (O.R.) for comparison of allele distribution with 95% 
Confidence Intervals (C.I.). Multivariate binary logistic regression was used to assess 
independent variables including sex, alcohol usage and age of infection in relation to 
APOE status in HCV antibody positive patients. All additional computations were 
performed using SPSS-10 for windows. 
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Results 
Comparing all patients versus healthy controls there was a significantly lower 
frequency of the E2,E2 genotype in the diseased population (χ2 = 7.34, p=0.0067).  
 
Table 1: APOE genotype and allele distribution (numbers and percentage) for HCV 
infected patients and healthy controls. 
  
APOE 
genotype 
Controls 
(n=288) 
HCV cohort 
(n=420) 
Probability 
(p) 
E2,E2 5 (2%)* 0* 0.0067 
E2,E3 32 (11%) 39 (9%) NS 
E2,E4 11 (4%) 9 (2%) NS 
E3,E3 167 (58%) 263 (63%) NS 
E3,E4 66 (23%) 105 (25%) NS 
E4,E4 7 (2%) 4 (1%) NS 
 
Comparison of the APOE genotypes in the two clinical subgroups (table 2) patients 
with spontaneously resolved infection (HCV RNA negative cleared infection; n = 
108) versus chronic infection (HCV RNA positive chronic infection; n = 312) 
demonstrated that the genotypes E2,E3 and E2,E4 were mostly strongly associated 
with clearance of HCV (p = 0.005, GRR E2,E3 = 0.36 CI 0.18 – 0.73 and p=0.02, 
GRR E2,E4 = 0.2 CI 0.52- 0.78, respectively). In addition whilst there was a 
significant effect of the E3,E4 genotype (p = 0.022, GRR = 0.55 CI 0.33 – 0.92) the 
E4,E4 genotype was not significant (p = 0.811)  due to the low number in the 
comparator subgroups. Comparing allele distribution the lowest risk of chronic 
infection was associated with the E2 allele (OR = 0.39, C.I. 0.21 – 0.73) compared to 
the E4 allele (OR = 0.59, C.I. 0.38 – 0.96). 
 
Table 2: APOE genotype distribution (numbers and percentage) in patients with 
spontaneously resolved infection (HCV RNA negative cleared infection) versus 
chronic infection (HCV RNA positive chronic infection)  
 
APOE 
genotype 
chronic 
HCV 
infection 
(n=312) 
cleared 
HCV 
infection 
(n=108) 
GRR 
(95% C.I) 
Probability 
(p) 
E2,E2 0 0 - - 
E2,E3 23 (7.5%) 16 (15%) 0.36 
(0.18 – 0.73) 
0.005 
E2,E4 4 (1%) 5 (4%) 0.20 
(0.52 – 0.77) 
0.020 
E3,E3 210 (67.5%) 53 (49%) 1 - 
E3,E4 72 (23%) 33 (31%) 0.55 
(0.33 – 0.92) 
0.022 
E4,E4 3 (1%) 1 (1%) 0.76 
(0.77 – 7.42) 
ns 
 
 8 
APOE*2 was the only independent predictor of viral clearance in a multivariate 
logistic regression model. No other significant associations were found comparing 
patients and controls, or comparing those with chronic versus those with resolved 
HCV infection.  In addition there was no significant association between APOE 
genotype or APOE alleles and the clinical phenotypes defined by severe inflammation 
(Ishak grade >8, n = 37), severe fibrosis (Ishak stage 5 and 6, n = 45) or fast fibrosis 
(rate of fibrosis ≥0.25/year, n = 60).  
 
Discussion 
Apolipoprotein E plays an important role in the transport of cholesterol and other 
lipids among cells of various tissues. Three major isoforms, encoded by three 
common alleles at the APOE locus, have different binding affinities for the Apo E 
receptors. The E2 allele is associated with defective binding to LDLr and the E4 allele 
with down regulation of LDLr compared to E3 31. In this study APOE*2 and APOE4 
alleles were both associated with an increased likelihood of viral clearance and, 
interestingly, there were no HCV antibody positive patients with the APOE E2,E2 
genotype, though this is relatively rare in healthy controls (0.5-2%) 37. A previous 
investigation of the influence of APOE polymorphism and outcome of HCV infection 
32
 suggested that the APOE*4 allele protected against severe liver disease. Our results 
did not confirm this finding but did suggest that this allele may also be associated 
with a reduced risk of viral persistence. However it is probable that neither this nor 
the earlier study is adequately powered to look at subtle effects of the Apo-ε4 isoform 
on disease progression. This latter comment is especially true when other factors 
associated with disease progression which may vary between cohorts are considered 9. 
Another small study has suggested that heterozygosity for the APOE*4 allele might 
be associated with better histological outcome in recurrent HCV infection in the liver 
transplantation setting 38, but this situation is complicated by possible differences in 
donor/recipient APOE alleles. It is also of interest that chronic HCV is associated with 
cognitive dysfunction and CNS infection 39 and a recent study has demonstrated an 
association between APOE*4  and neuro-psychiatric symptoms during interferon 
alpha treatment for chronic HCV 40.  
The association found between the E2 allele and viral clearance is intriguing as this 
allele binds poorly to LDLr 31. It is plausible that such defective binding could result 
in poor uptake of HCV lipo-viral particles into the hepatocyte with a resultant 
decrease in replication of the virus, thus altering the balance between virus replication 
and the immune response and favouring clearance of the virus before chronic 
infection can be established. This is supported by the lack of E2,E2 genotype among 
patients who are HCV antibody positive, suggesting that the E2,E2 genotype (0.5-2% 
of healthy controls 37) may confer relative resistance to establishing HCV infection in 
exposed individuals. This could be somewhat analogous to the role played by the 
chemokine receptor-5 delta 32 mutation, which leads to defective uptake of the HIV 
virion and therefore resistance to HIV/AIDS 41. In the latter case, homozygotes for the 
delta 32 mutation exhibit a strong, although incomplete, resistance to HIV infection, 
whereas heterozygotes display delayed progression to acquired immunodeficiency 
syndrome.  Conversely the results reported here may indicate an association between 
the APOE*3 allele and persistence of hepatitis C virus. This would fit a model 
whereby APOE*3 binds to receptors with high affinity and is associated with normal 
serum cholesterol and triglyceride levels.  
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In conclusion this study suggests that common genetic variations at the APOE locus 
influence the outcome of HCV infection with the APO*E2 and APO*E4 alleles 
favouring viral clearance. We hypothesise that ApoE2, which binds poorly with its 
receptors, may be associated with resistance to HCV infection, via defective uptake of 
HCV lipo-viral particles by the candidate receptors LDLr and SR-B1. Further 
investigations are needed, especially in individuals who are likely to have been 
repeatedly exposed to HCV but remain anti-HCV antibody negative 42. Although the 
inability to replicate the results of case-control studies has led to scepticism about 
their value 43 , our findings are both biologically plausible and statistically significant. 
If our findings are confirmed in a validation study, the function of Apolipoprotein E 
in assembly, processing and removal of plasma lipoproteins and its interaction with 
HCV could be considered in the development of novel therapeutic strategies. 
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